Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy

Katiuscia O'Brian, Suhong Luo, Arun Ganti, Peter Riedell, Ryan C. Lynch, Ryan Roop, Kristen M. Sanfilippo, Weijian Liu, Graham A. Colditz, Kenneth R. Carson

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Identifying weight changes associated with treatment of diffuse large B-cell lymphoma (DLBCL) has the potential to improve the long-term health of survivors. A retrospective cohort of United States veterans with a new diagnosis of DLBCL between October 1, 1998 and September 30, 2008, with follow-up until April 23, 2013, was assembled. Weight changes were evaluated before, during, and after treatment in 1935 DLBCL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP+/- R). One year prior to treatment, 79% of patients were obese or overweight. During the 12 months leading up to treatment, 57% of the cohort lost weight. Among patients surviving 24 months after treatment initiation, weight increased an average of 2.9 kg above weight at treatment completion. The weight change trends observed in these DLBCL patients suggest that weight management strategies may be an important part of long-term survivorship planning after conclusion of treatment.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2016

Keywords

  • CHOP chemotherapy
  • lymphoma
  • veterans
  • weight change

Fingerprint Dive into the research topics of 'Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy'. Together they form a unique fingerprint.

Cite this